CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
Key Highlights
- ➤CVRx (CVRX) to present Barostim data across eight HFSA 2026 events
- ➤REBALANCE Registry analyses will assess Barostim safety and benefits in commercial use
- ➤HFmrEF real-world evidence addresses reduced hospitalization burden with Barostim
- ➤BENEFIT-HF expanded-population trial featured in HFSA clinical trial ePoster hub
- ➤CVRx (CVRX) will host two symposia on Barostim heart-failure care integration
Expert Statements
Kevin Hykes, President and Chief Executive Officer of CVRx
“We are excited by the scientific interest in Barostim at this year’s HFSA conference, with four separate data sets, five podium discussions and two symposia focused on practical elements for incorporating Barostim into clinical practice.”
Kevin Hykes, President and Chief Executive Officer of CVRx
“The data being presented provide important new scientific insights about Barostim across patient populations, clinical outcomes and real-world practice, contributing to a broader understanding of its role in the heart failure continuum.”
MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations featuring Barostim at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026. The meeting will be held Oct. 9-12, 2026, in Phoenix.
Barostim will be featured across eight events at HFSA, including late-breaking clinical data, a rapid-fire session, posters and podium sessions. BENEFIT-HF, the landmark clinical trial initiated earlier this year evaluating Barostim in an expanded population, will also be included in the clinical trial ePoster hub.
Get started
Create a free account to read the full story.